Bronchial asthma due to alpha-methyldopa Asthma from inhaling alpha-methyldopa powder was demonstrated by occupational type bronchial provocation testing in a woman who was handling the powder in a drug factory.
Case report
A 27-year-old woman started work in 1973 as an analytical chemist in a factory making methyldopa tablets. Two to three months later she developed blockage of the nose and repeated sneezing at work, which improved after three weeks. Her symptoms appeared intermittently with increasing frequency. She noted that they seemed to occur when methyldopa powder was present in the room. Six months before her referral to hospital she developed exercise-induced asthma. This was better when away from work on holiday.
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Lactose powder 500g 30min Non-immediate asthmatic reaction resulting from 30 minutes' exposure to alpha-methyldopa dust, maximal at 11 hours.
Recovery incomplete 22 hours later.
She was non-atopic and a prick test for sensitivity to alpha-methyldopa was negative. She had no serum precipitins to the drug and both direct and indirect Coombs tests were negative. She was admitted to hospital in May 1978.
Provocation tests were done in a ventilated sealed chamber measuring 6 cubic metres. She was exposed to methyldopa by pouring 100 g of powder between two trays for 30 minutes. After this challenge FEV1 and FVC were measured with a dry wedge spirometer (Vitalograph) every five minutes for 30 minutes, then every 10 minutes for 30 minutes, and thereafter every hour for 12 hours. Control readings were made in the same way on a separate day after tipping dried lactose powder for 30 minutes. A fall in FEV, of 15 % or more after challenge compared with lactose control was regarded as a significant bronchial reaction. Bronchial reactivity to histamine acid phosphate nebulised for 30 seconds up to a final concentration of 32 mg/ml was also measured on a separate day. Nine hours after exposure to alphamethyldopa powder the patient complained of nasal stuffiness and sneezing, and 11 hours after she complained of tightness in the chest and wheezing. Her FEV1 fell by 30°from 2-66 1 to 185 1 maximal at 11 hours (figure).
There was no such asthmatic reaction to lactose control or to histamine.
Comment
Similar asthmatic reactions have been described in other pharmaceutical industry workers after inhaling the powders of piperazine dihydrochloridel; ampicillin, benzyl penicillin, and 6-aminopenicillanic acid2; spiramycin3; glycyl compounds; fenfluoramine4; and clam's liver extract used in cancer chemotherapy.5 Asthma has also resulted from the ingestion of tetracycline in a sensitive subject. We were unable to demonstrate antibodies to alpha methyldopa in our patient, but she alone of those working with the drug developed rhinitis and asthma. These started after several months' exposure without symptoms, suggesting that they were allergic reactions. Since the diagnosis was made she has avoided exposure to alpha-methyldopa, with complete remission of symptoms.
Reversible haemolytic anaemia after levodopa-carbidopa A positive direct Coombs test and rarely autoimmune haemolytic anaemia (AIHA) are well-known complications of methyldopa treatment, particularly when given at higher dosage.' Patients taking levodopa may also have a positive Coombs test, and a few have developed AIHA.' The positive Coombs test is due to a warm-reacting IgG autoantibody with rhesus specificity indistinguishable from that seen in idiopathic AIHA but becoming weak or negative within a few weeks after stopping the drug. In one case of AIHA3 Parkinsonian disability became so severe after stopping levodopa that after two weeks it was reinstated, though at one-sixth the previous dose by using the dopa-decarboxylase inhibitor combination levodopabenserazide (Madopar). The Coombs test remained positive but haemolysis did not recur. The following case, however, which was originally described by Barat et al,4 shows for the first time that severe AIHA may develop with combination chemotherapy.
Case report
In 1969 a 65-year-old Frenchman developed Parkinson's disease. Levodopa was prescribed in 1974, the dose gradually being increased to 6 g daily. The
